Dyne Therapeutics prices $325.5M public offering of 10.5M shares at $31.00 per share

Dyne Therapeutics, Inc.

Gross proceeds of $325.5M; net proceeds estimated at $305.4M ($351.4M if underwriters' option is fully exercised).
Underwriters include Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities; closing expected May 24, 2024.
Company granted 30-day option for underwriters to purchase an additional 1.575M shares at the same price.
Net proceeds plus existing cash expected to fund operations at least into the second half of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.